Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
The first comprehensive long-term study comparing different medications for type 2 diabetes is launching nationwide. The GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness) Study will compare the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating type 2 diabetes.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64578-grade-glycemia-reduction-approaches-in-diabetes-comparative-effectiveness
With the start of the holiday season comes the start of party season! Getting glammed up for parties can be tricky and time consuming: thought must be given to everything from how to style your hair and what to wear to how to apply makeup to look fun and festive.
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
TriggerPoint™, the market leader in foam rolling, movement products and education, today announces the launch of the GRID VIBE premium vibrating foam roller. Designed for muscle relaxation and pain reduction, the GRID VIBE pairs TriggerPoint’s patented GRID foam roller design with vibration technology to deliver enhanced muscle mobility experiences.
The GRID VIBE’s vibration frequency is specifically calibrated at 33 hertz for optimal muscle relaxation, minimizing discomfort and allowing users to focus longer on foam rolling tender areas. Research shows that vibration decreases the body’s sensation of pain. When vibration is paired with TriggerPoint’s signature GRID pattern that mimics a massage therapist’s hands, fingers and fingertips, the GRID VIBE effectively targets more layers of tight muscle tissue. The GRID VIBE can be used by anyone for muscle recovery, injury prevention, improving athletic performance, pain management, or boosting overall body movement and mobility.
To view the multimedia release go to:
https://www.multivu.com/players/English/8135751-triggerpoint-grid-vibe-vibrating-foam-roller/
TriggerPoint™, the market leader in foam rolling, movement products and education, today announces the launch of the GRID VIBE premium vibrating foam roller. Designed for muscle relaxation and pain reduction, the GRID VIBE pairs TriggerPoint’s patented GRID foam roller design with vibration technology to deliver enhanced muscle mobility experiences.
The GRID VIBE’s vibration frequency is specifically calibrated at 33 hertz for optimal muscle relaxation, minimizing discomfort and allowing users to focus longer on foam rolling tender areas. Research shows that vibration decreases the body’s sensation of pain. When vibration is paired with TriggerPoint’s signature GRID pattern that mimics a massage therapist’s hands, fingers and fingertips, the GRID VIBE effectively targets more layers of tight muscle tissue. The GRID VIBE can be used by anyone for muscle recovery, injury prevention, improving athletic performance, pain management, or boosting overall body movement and mobility.
To view the multimedia release go to:
https://www.multivu.com/players/English/8135751-triggerpoint-grid-vibe-vibrating-foam-roller/
Recognizing an opportunity to create a better world through innovative energy solutions, ENGIE Resources, the third-largest non-residential electricity provider in the United States, has unveiled a new program designed to put more power where it belongs – in the hands of customers.
Called the “Energy Revolution,” the effort seeks to shift the emphasis away from providers’ traditional role, which has been to help customers manage price risk alone, and toward helping customers manage both price and quantity – how much they use, when they use it, and what they pay.
To view the multimedia release go to:
https://www.multivu.com/players/English/8071951-engie-resources-leads-energy-revolution/
